Business strategyas a rheumatism and orthopedics specialty pharma company

Synergies from relationships with medical practitioners cultivated by each of AYUMI and Showa Yakuhin Kako

AYUMI knows that information about the effectiveness and safety of drugs is extremely important. We have therefore conducted activities that include voluntary post-launch market research, even for generics, in order to provide careful feedback to rheumatism doctors.
In addition, Showa Yakuhin Kako’s medical drugs business has expanded its offerings of patient psychological support information and information on the efficacy and safety of “pain relief” products, primarily for clinical orthopedics specialists.
The merger of the two companies will enable even more comprehensive information to be disseminated to a wider range of practitioners in the future.

“Pain relief” is a topic of major importance in the treatment of many illnesses, including rheumatism. Because alleviating pain, and rehabilitation and exercise therapy, are indispensable for orthopedics treatment, collaboration with medical practitioners in orthopedics and other fields will increase in importance in the future.
The analgesic Calonal was the leading product at the medical drugs division of Showa Yakuhin Kako, which now forms part of AYUMI. Calonal has won the trust of doctors and pharmacists by having few side effects, and boasts the top share (80%^※) of the market for acetaminophen products.
AYUMI will help create an environment in which effective and comprehensive information can be provided together with Calonal, so that patients receive appropriate treatment at an early stage.

※ According to prescription information analysis service data from Japan Medical Information Research Institute Inc. (JMIRI) as of the end of October 2015

Business vision

AYUMI is helping to improve the quality of life of patients, by promoting relationships with medical personnel, fostering R&D and cultivating human resources in the areas of rheumatism and orthopedics. We will strive to build a “rheumatism and orthopedics open platform” in the areas of osteoarthritis and osteoporosis as well as rheumatoid arthritis and pain relief. With it, we intend to promote such things as the development of new drugs, development and introduction of biological drugs and biosimilars, and business alliances with other companies and research institutions, in order to make AYUMI everyone’s go-to brand for rheumatism and orthopedics.